Carol Wysham, ADA 2022: Tirzepatide for type 2 diabetes, post-hoc analysis of the SURPASS trials
The SURPASS trials demonstrated the efficacy and safety of tirzepatide for type 2 diabetes. Dr Carol Wysham (MultiCare Rockwood Clinic, Spokane, WA, USA) discusses the outcomes of a post-hoc analysis of the SURPASS programme and the impact of tirzepatide on clinical practice following its recent FDA approval.
The abstract entitled ‘Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- What has the SURPASS clinical trial programme taught us about the efficacy and safety of tirzepatide in the treatment of patients with type 2 diabetes? (0:25)
- Which subpopulations were evaluated in the post-hoc analysis you are presenting? (1:25)
- What were the findings of these analyses? (1:56)
- What is the safety profile of tirzepatide? (2:46)
- Following the recent FDA approval of tirzepatide, what do you expect to be its impact on clinical practice? (3:40)
Disclosures: Carol Wysham has received grant/research support from Abbott, Corcept, Eli Lilly, Novo Nordisk, Regeneron and Vanda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022 in diabetes
2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!